On the morning of July 1, 2022, Zeng Bin, Secretary-General of Chengdu High-tech Medical Association, Lin Fan, Deputy Secretary-General, and Bu Wei, Deputy Director of the Collaborative Innovation Center for Medical-Industrial Integration, went to Chengdu Tetrahedron Drug Research Co., Ltd. to promote the transformation of scientific and technological achievements. , promoting the development of the pharmaceutical industry and other aspects of friendly exchanges and discussions.

     After visiting the laboratory of Tetrahedron Drug Research Co., Ltd., the delegation of the society conducted exchanges and discussions. Five core members including the company's chairman Yu Luoting and general manager Chen Shaowu attended the meeting.

     Yu Luoting, chairman of Tetrahedron, said: In the research and development of new drugs against drug-resistant strains, differentiated research and development is the basic concept of the company's development. Relying on high-tech preferential policies and advanced conditions, with the help of the platform of the High-tech Medical Association, it will promote the transformation of scientific and technological achievements in colleges and universities , to promote the development of medical and health undertakings and improve social and people's livelihood.

     Zeng Bin, secretary-general of Chengdu High-tech Medical Association, said: The society has always adhered to the work philosophy of "strengthening the grassroots and promoting transformation", taking the promotion of medical innovation-driven and medical-industrial integration as its own responsibility, and is committed to providing full-industry chain services for high-tech and biomedical research and development. Promote the recruitment of talents, the transformation of achievements and the implementation of industrial projects.

     In the end, the two sides reached a consensus: they will be committed to promoting the construction of the biomedical health industry, and work together to jointly build a new model of the pharmaceutical ecosystem and promote inclusive development.

Editor in charge: Cao Lisha

Review: Lin Fan